Dr. Tahir Latif, MD
Claim this profileUniversity of Cincinnati Cancer Center-UC Medical Center
Studies Cancer
Studies B-Cell Lymphoma
11 reported clinical trials
32 drugs studied
Area of expertise
1Cancer
CCND1 positive
t(11;14) positive
Stage IV
2B-Cell Lymphoma
Affiliated Hospitals
Clinical Trials Tahir Latif, MD is currently running
Cema-cel
for B-Cell Lymphoma
This is a randomized, open-label study in adult patients who have completed standard first line of therapy for large B-cell lymphoma (LBCL) and achieved a complete response or partial response suitable for observation, but who have minimal residual disease (MRD) as detected by the Foresight CLARITY™ Investigational Use Only (IUO) MRD test, powered by PhasED-Seq™. The purpose of the trial is to assess the efficacy and safety of consolidation with cemacabtagene ansegedleucel (cema-cel), an allogeneic CD19 CAR T product, as compared to standard of care observation. The study is conducted in 2 consecutive parts that will be enrolled continuously. In Part A of the study, participants with MRD are randomized to one of two treatment arms or an observation arm. Treatment includes cema-cel following a lymphodepletion regimen of fludarabine and cyclophosphamide administered with or without the anti-CD52 monoclonal antibody, ALLO-647. Part A will culminate with the selection of the lymphodepletion regimen to advance to Part B. Part B will evaluate the selected lymphodepletion regimen followed by cema-cel as compared with observation.
Recruiting1 award Phase 25 criteria
IMPT-314
for Non-Hodgkin's Lymphoma
This is a Phase 1/2, multi-center, open-label study evaluating the safety and efficacy of IMPT-314, a bispecific chimeric antigen receptor (CAR) targeting cluster of differentiation (CD)19 and CD20 in participants with aggressive B-cell NHL. Three cohorts of participants will be enrolled: 1) CAR T naïve after at least two or more prior lines of treatment, 2) CAR T experienced and 3) refractory disease or relapse within one year of first line therapy. Up to approximately 90 patients (30 per cohort) will be enrolled in dose finding Phase 1 part of the study, which will determine the recommended phase 2 dose. Phase 2 will enroll up to approximately 60 additional participants (20 per cohort) to evaluate further the safety and efficacy of IMPT-314. IMPT-314 treatment consists of a single infusion of CAR-transduced autologous T cells administered intravenously after a conditioning chemotherapy regimen consisting of fludarabine and cyclophosphamide, administered over 3 days. Individual participants will remain in the active post-treatment period for approximately 2 years. Participants will continue in long-term follow-up for 15 years from treatment.
Recruiting1 award Phase 1 & 2
More about Tahir Latif, MD
Clinical Trial Related2 years of experience running clinical trials · Led 11 trials as a Principal Investigator · 3 Active Clinical TrialsTreatments Tahir Latif, MD has experience with
- Rituximab
- Autologous Hematopoietic Stem Cell Transplantation
- Brentuximab Vedotin
- ALLO-647
- ALLO-501A
- Irinotecan
Breakdown of trials Tahir Latif, MD has run
Cancer
B-Cell Lymphoma
Lymphoma
Non-Hodgkin's Lymphoma
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Tahir Latif, MD specialize in?
Tahir Latif, MD focuses on Cancer and B-Cell Lymphoma. In particular, much of their work with Cancer has involved CCND1 positive patients, or patients who are t(11;14) positive.
Is Tahir Latif, MD currently recruiting for clinical trials?
Yes, Tahir Latif, MD is currently recruiting for 3 clinical trials in Cincinnati Ohio. If you're interested in participating, you should apply.
Are there any treatments that Tahir Latif, MD has studied deeply?
Yes, Tahir Latif, MD has studied treatments such as Rituximab, Autologous Hematopoietic Stem Cell Transplantation, Brentuximab Vedotin.
What is the best way to schedule an appointment with Tahir Latif, MD?
Apply for one of the trials that Tahir Latif, MD is conducting.
What is the office address of Tahir Latif, MD?
The office of Tahir Latif, MD is located at: University of Cincinnati Cancer Center-UC Medical Center, Cincinnati, Ohio 45219 United States. This is the address for their practice at the University of Cincinnati Cancer Center-UC Medical Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.